|
See related Zestril tab information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
DKSH |
|
Contents |
Lisinopril dihydrate |
|
Indications |
Listed in Dosage. |
|
Dosage |
Essential HTN Initially 10 mg daily. Maintenance: 20 mg once daily. Renovascular HTN Initially 2.5-5 mg, may be adjusted according to response. CHF Initially 2.5 mg once daily. Range: 5-20 mg in single daily dose. Acute MI Initially 5 mg followed by 5 mg after 24 hr, 10 mg after 48 hr, then 10 mg once daily thereafter. Renal complications of DM Normotensive IDDM patients or hypertensive NIDDM 10 mg once daily, may increased to 20 mg once daily. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Angioedema associated w/ ACE inhibitors & in patients w/ hereditary or idiopathic angioedema. |
|
Special Precautions |
Symptomatic hypotension particularly in vol-depleted patients & CHF. Hypotension may occur during surgery/anesth. Patients w/ ischemic heart or cerebrovascular disease. Aortic stenosis or hypertrophic cardiomyopathy. Renal impairment. History of angioedema. Pregnancy, lactation. Anaphylactoid reactions reported in patients undergoing hemodialysis & desensitization treatments. |
|
Adverse Drug Reactions |
Dizziness, headache, diarrhoea, fatigue, cough, nausea, rash, orthostatic effects, asthenia. Rarely, angioedema, MI, CVA possibly secondary to excessive hypotension in high risk patients, palpitations, tachycardia, abdominal pain & indigestion, dry mouth, hepatitis, jaundice, vomiting, mood alterations, mental confusion, vertigo, urticaria, diaphoresis, uraemia, oliguria/anuria, renal dysfunction, acute renal failure, impotence, a symptom complex which may include fever, vasculitis, myalgia, arthralgia/arthritis, positive ANA, elevated ESR, eosinophilia & leukocytosis. Rash, photosensitivity or other dermatological manifestations. Increases (usually reversible) in blood urea, serum creatinine, liver enzymes & serum bilirubin. Small decreases in Hb & hematocrit. Hyperkalemia, hyponatremia, leucopenia, thrombocytopenia, bone marrow depression, manifest as anaemia, paraesthesia, pancreatitis. Rarely, haemolytic anaemia.
View ADR Monitoring Form |
|
Drug Interactions |
Risk of hyperkalemia w/ K-sparing diuretics, K supplements, K-containing salt substitutes. Antihypertensive effect may be diminished by indomethacin. Additive antihypertensive effects w/ diuretics. May reduce lithium elimination. ACE inhibitors may potentiate the hypoglycaemic effect of insulin & oral antidiabetic drugs.
View more drug interactions with Zestril |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
